Genomic Testing Cooperative to Present Data at the American Society of Hematology Meeting on New Applications of its Proprietary Tests that Combine Transcriptome Data Obtained from Tissue or Liquid biopsies with Machine Learning

ASH 2022 - GTC - AI

Irvine, California– December 6, 2021 – Genomic Testing Cooperative, LCA (GTC) announced the presentation of four innovative studies at the annual American Society of Hematology (ASH) meeting that will be held from December 10 to 13, 2022 in New Orleans, Louisiana.   The studies highlight and validate the value of the extended molecular profiling testing currently offered by GTC in evaluating hematologic neoplasms using DNA and RNA next generation sequencing (NGS). 

GTC reports that by combining targeted transcriptome with a proprietary machine learning algorithm, they can predict which patients with advanced myelodysplastic syndrome/acute myeloid leukemia will respond to treatment with Venetoclax-based therapy.  In another study, GTC demonstrates that combining targeted transcriptome with machine learning can predict which patients will develop acute graft-versus-host disease (aGVHD) not only post-transplant, but also using pre-transplant sample, which suggests that the patient’s own bone marrow microenvironment may contribute to the development of aGVHD.  

GTC continues to demonstrate the superior capabilities of their new cell-free (cfDNA) and cell-free RNA (cfRNA) liquid biopsy test called Liquid Trace™.  Using cfRNA, GTC studies show that the cfRNA levels can be used in “liquid immunoprofiling” of hematologic neoplasms.  Combining this liquid immunophenotyping with machine learning algorithms report high reliability in the differential diagnosis between various types of lymphoid neoplasms/lymphoma.  

A fourth study explored the disparity in somatic mutations and outcome in primary central nervous system lymphoma between Hispanic and non-Hispanic patients.  

“The work presented at ASH reflects the commitment of GTC to be the leading diagnostic company in innovation and in advancing the science of diagnostics and biomarkers discovery, especially in hematologic neoplasms,” said Dr. Maher Albitar, founder, chief executive officer and chief medical officer of GTC.   “The use of RNA profiling in tissue and liquid biopsies is opening new horizons in diagnostics, especially when combined with artificial intelligence.  Because of the collaborative business model adapted by GTC as a cooperative (Co-Op) company, we are able to lead in this field.  The commitment of all members of the Co-Op to work closely with GTC to improve patient care and advance precision medicine made this work possible” added Dr. Albitar.

Following is a list of GTC presentations:

1)           DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy.  December 11, 2022: 6:00 PM-8:00 PM

2)           Liquid Immunophenotyping and the Diagnosis of Lymphoid Neoplasms Using Cell-Free RNA.  Sunday, December 11, 2022: 6:00 PM-8:00 PM

3)           Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute GVHD (aGVHD) and Overall Survival after Allogeneic HSC Transplantation.   Saturday, December 10, 2022: 5:30 PM-7:30 PM

4)           Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity.   Saturday, December 10, 2022: 5:30 PM-7:30 PM

Please visit GTC booth #205 at the ASH exhibit hall for more information.

About Genomic Testing Cooperative, LCA

Genomic Testing Cooperative (GTC) is a privately-owned molecular testing company located in Irvine, CA. The company operates based on a cooperative (co-op) business model.  Members of the co-op hold type A shares with voting rights. The company offers its patron members a full suite of comprehensive genomic profiling based mainly on next generation sequencing.  Molecular alterations are identified based on rigorous testing with the aid of specially developed algorithms to increase accuracy and efficiency. The clinical relevance of the detected alterations is pulled from numerous databases using internally developed software. Relevance of findings to diagnosis, prognosis, selecting therapy, and predicting outcome are reported to members. The co-op model allows GTC to make the testing and information platform available to members at a lower cost because of a lower overhead. For more information, please visit 

Forward Looking Statements

All of the statements, expectations and assumptions contained in this press release are forward-looking statements. Such forward-looking statements are based on the GTC management’s current expectations and includes statements regarding the value of comprehensive genomic profiling, RNA profiling, DNA profiling, algorithms, therapy, the ability of testing to provide clinically useful information. All information in this press release is as of the date of the release, and GTC undertakes no duty to update this information unless required by law.

Company contact:

Jennifer Varca

Genomic Testing Cooperative.

(949) 540-9421


Subscribe to our Newsletter

Get all the critical news and events sent straight to your inbox

Share this post with your friends